![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
Details:
Abreva® (Docosanol cream 10%) in a 2 gm tube and pump formats,is used to treat "cold sores/fever blisters" (herpes labialis). It can speed up healing of the sores and decrease symptoms.
Lead Product(s): Docosanol
Therapeutic Area: Infections and Infectious Diseases Product Name: Abreva
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alembic Pharmaceuticals Limited
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
Docosanol is a drug used for topical treatment for recurrent herpes simplex labialis episodes, inhibits fusion between plasma membrane and herpes simplex virus envelope, thereby preventing viral entry into cells and subsequent viral replication.
Lead Product(s): Docosanol
Therapeutic Area: Infections and Infectious Diseases Product Name: Docosanol-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022